title: SERPINA1 Gene
SERPINA1 Gene
Overview
SERPINA1 encodes alpha-1 antitrypsin (A1AT), a member of the serpin superfamily of serine protease inhibitors. While classically studied in the context of lung emphysema and liver disease due to deficiency states, emerging evidence positions SERPINA1 as a significant player in neurodegenerative disease pathogenesis. Alpha-1 antitrypsin functions as an acute-phase protein with broad anti-inflammatory properties, including inhibition of neutrophil elastase, cathepsin G, and proteinase-3. In the central nervous system, A1AT is produced by astrocytes and microglia, where it modulates neuroinflammation, oxidative stress, and proteostasis—all key processes in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) pathogenesis. [@stolk2019]
<div class="infobox infobox-gene"> [@uniprot]
| Property | Value |
|----------|-------|
| Gene Symbol | SERPINA1 |
| Gene Name | Serpin Family A Member 1 (Alpha-1 Antitrypsin) |
| Chromosomal Location | 14q32.13 |
| NCBI Gene ID | [5265](https://www.ncbi.nlm.nih.gov/gene/5265) |
| OMIM | [107400](https://www.omim.org/entry/107400) |
| UniProt | [P01009](https://www.uniprot.org/uniprot/P01009) |
| Ensembl | [ENSG00000197249](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197249) |
| RefSeq mRNA | NM_001002236 |
| Protein Length | 418 amino acids |
</div>
Protein Structure and Function
...title: SERPINA1 Gene
SERPINA1 Gene
Overview
SERPINA1 encodes alpha-1 antitrypsin (A1AT), a member of the serpin superfamily of serine protease inhibitors. While classically studied in the context of lung emphysema and liver disease due to deficiency states, emerging evidence positions SERPINA1 as a significant player in neurodegenerative disease pathogenesis. Alpha-1 antitrypsin functions as an acute-phase protein with broad anti-inflammatory properties, including inhibition of neutrophil elastase, cathepsin G, and proteinase-3. In the central nervous system, A1AT is produced by astrocytes and microglia, where it modulates neuroinflammation, oxidative stress, and proteostasis—all key processes in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) pathogenesis. [@stolk2019]
<div class="infobox infobox-gene"> [@uniprot]
| Property | Value |
|----------|-------|
| Gene Symbol | SERPINA1 |
| Gene Name | Serpin Family A Member 1 (Alpha-1 Antitrypsin) |
| Chromosomal Location | 14q32.13 |
| NCBI Gene ID | [5265](https://www.ncbi.nlm.nih.gov/gene/5265) |
| OMIM | [107400](https://www.omim.org/entry/107400) |
| UniProt | [P01009](https://www.uniprot.org/uniprot/P01009) |
| Ensembl | [ENSG00000197249](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197249) |
| RefSeq mRNA | NM_001002236 |
| Protein Length | 418 amino acids |
</div>
Protein Structure and Function
Alpha-1 antitrypsin is a 52 kDa glycoprotein synthesized primarily in the liver, with extrahepatic expression in astrocytes, microglia, and macrophages throughout the body. The protein possesses a characteristic serpin fold with a reactive center loop (RCL) that acts as a bait for target proteases. Upon proteolytic cleavage, A1AT undergoes a dramatic conformational change, forming a stable complex with the protease and rendering it inactive. [@lomas2008]
The physiological functions of A1AT extend well beyond its canonical protease inhibitory activity:
Anti-inflammatory Effects: A1AT reduces cytokine production from activated microglia, limits neutrophil infiltration, and attenuates inflammasome activation. The protein exerts these effects partly through direct interaction with CD95/Fas receptor, promoting anti-apoptotic signaling. [@golder2020]
Antioxidant Properties: A1AT scavenges reactive oxygen species (ROS) and upregulates cellular antioxidant defenses through Nrf2 pathway activation. SERPINA1 deficiency results in increased oxidative stress markers in neural tissues. [@butters2019]
Proteostasis Regulation: As a serpin, A1AT interacts with the protein folding machinery and can influence aggregate formation. In vitro studies demonstrate that A1AT can modify amyloid-beta aggregation kinetics and tau pathology. [@hernandez2018]
Immunomodulation: A1AT modulates T-cell activation and promotes regulatory B-cell function. These effects have therapeutic implications for autoimmune components of neurodegeneration. [@popa2021]Expression in the Brain
Within the central nervous system, alpha-1 antitrypsin is expressed at low basal levels but is upregulated during neuroinflammation. Astrocytes constitute the primary source of CNS-derived A1AT, with microglia producing the protein in response to inflammatory stimuli. Cerebrospinal fluid (CSF) concentrations of A1AT are approximately 1/100th of plasma levels but increase proportionally with systemic inflammation. Importantly, the blood-brain barrier restricts A1AT transit under normal conditions, though neuroinflammation may increase permeability.
Disease Associations
Alzheimer's Disease
Multiple lines of evidence implicate SERPINA1 variants and A1AT levels in AD pathogenesis:
- Genetic Association: Genome-wide association studies (GWAS) have identified SERPINA1 polymorphisms associated with altered AD risk. The PiZ allele (E342K) and PiS allele (E264V) variants demonstrate variable effects on disease risk across populations. [@zhang2019]
- Aβ Modulation: A1AT directly interacts with amyloid-beta (Aβ) peptides, inhibiting fibril formation and promoting non-amyloidogenic aggregation. CSF A1AT levels correlate with Aβ42 levels, suggesting a role in amyloid clearance.
- Neuroinflammation: Elevated A1AT levels in AD brains correlate with microglial activation markers. The protein's anti-inflammatory properties suggest a compensatory role in limiting neuroinflammation, though dysregulated expression may contribute to disease progression. [@mueller2019]
- Tau Pathology: Emerging evidence indicates A1AT can interact with hyperphosphorylated tau, potentially influencing neurofibrillary tangle formation. Animal models demonstrate that SERPINA1 deficiency exacerbates tau pathology.
Parkinson's Disease
In PD, SERPINA1 demonstrates complex relationships with alpha-synuclein pathology:
- Alpha-Synuclein Interaction: A1AT binds to alpha-synuclein and inhibits its aggregation in vitro. This suggests a potential protective role in Lewy body formation.
- Microglial Activation: PD patients show elevated CSF A1AT levels, correlating with disease severity. The protein appears to modulate microglial activation in response to alpha-synuclein pathology. [@marchi2021]
- Oxidative Stress: Given the central role of oxidative stress in PD pathogenesis, A1AT's antioxidant properties may be particularly relevant. SERPINA1 polymorphisms associated with reduced protein function may increase PD risk.
- Neuroprotection: Exogenous A1AT administration protects dopaminergic neurons in toxin-based PD models, supporting a neuroprotective role.
Amyotrophic Lateral Sclerosis
SERPINA1 variants influence ALS susceptibility and progression:
- Genetic Studies: Multiple studies have identified SERPINA1 polymorphisms as modifiers of ALS age of onset and survival. The PiZ allele shows protective effects in some populations. [@galli2022]
- Neuroinflammation: A1AT's anti-inflammatory properties are relevant to the prominent neuroinflammation observed in ALS. The protein reduces motor neuron toxicity from activated microglia.
- Protein Aggregation: Given the role of TDP-43 aggregation in ALS, A1AT's chaperone-like properties may influence protein homeostasis.
Other Neurodegenerative Diseases
- Frontotemporal Dementia: SERPINA1 variants show modest associations with behavioral variant FTD
- Huntington's Disease: A1AT levels correlate with disease progression; potential therapeutic target
- Multiple Sclerosis: A1AT demonstrates immunomodulatory effects relevant to autoimmune demyelination
Genetic Variants
Over 100 SERPINA1 variants have been described, with the most clinically significant being:
| Variant | Designation | Effect | Clinical Relevance |
|---------|-------------|--------|-------------------|
| E342K (Glu342Lys) | PiZ | Severe deficiency | Emphysema, liver disease |
| E264V (Glu264Val) | PiS | Moderate deficiency | Liver disease risk |
| M1 Val213 | M1 | Normal function | Common polymorphism |
| R39C (Arg39Cys) | PiP | Deficiency | Emphysema |
The PiZ (Z) allele, present in approximately 2-4% of individuals of European descent, causes dramatic reductions in circulating A1AT due to protein misfolding and polymerization. Individuals with this variant demonstrate increased susceptibility to emphysema and liver disease, with emerging evidence for neurological complications.
Therapeutic Implications
Replacement Therapy
Alpha-1 antitrypsin augmentation therapy (AAT therapy), currently approved for pulmonary emphysema, has potential applications in neurodegeneration:
- Intravenous A1AT (Prolastin, Aralast, Zemaira) crosses the blood-brain barrier in neuroinflammatory states
- Phase I trials are evaluating safety in AD and PD patients
- Combination approaches with standard therapies show promise in preclinical models
Small Molecule Agonists
Development of SERPINA1 expression enhancers represents an alternative strategy:
- Agents that upregulate hepatic and CNS A1AT production
- Nrf2 activators indirectly increase SERPINA1 expression
- Gene therapy approaches for long-term expression
Mechanistic Targets
Understanding SERPINA1's roles in neurodegeneration identifies multiple therapeutic targets:
- Inflammasome Inhibition: A1AT blocks NLRP3 inflammasome activation
- Protease Balance: Restoring protease/antiprotease equilibrium
- Oxidative Stress: Enhancing Nrf2-mediated antioxidant responses
- Protein Aggregation: Modifying amyloid and tau aggregation
Animal Models
Several rodent models inform SERPINA1 function in neurodegeneration:
- SERPINA1 Knockout Mice: Show increased susceptibility to neuroinflammation and oxidative stress
- Transgenic Models: Overexpressing human SERPINA1 demonstrate neuroprotection
- AAV-Mediated Delivery: CNS-targeted gene therapy shows promise in PD models
Biomarker Potential
Alpha-1 antitrypsin possesses biomarker characteristics for neurodegeneration:
- CSF A1AT: Elevated in AD, PD, and ALS; correlates with disease severity
- Blood A1AT: Systemic inflammation marker; limited CNS specificity
- A1AT/ApoE Ratio: Potential diagnostic algorithm for AD
Research Directions
Key unanswered questions include:
- Mechanism of A1AT crossing the blood-brain barrier
- Optimal delivery route and formulation for CNS indications
- Biomarker validation in large cohort studies
- Combination therapy protocols with existing treatments
- Personalized medicine approaches based on SERPINA1 genotype
Pathway & Interaction Diagram
Interactive diagram showing SERPINA1's key relationships in the SciDEX knowledge graph (6 connections shown).
Mermaid diagram (expand to render)
References
[Greene et al., Alpha-1 antitrypsin deficiency (2020)](https://doi.org/10.1056/NEJMoa1910594)
[Stolk et al., SERPINA1 in COPD (2019)](https://doi.org/10.1183/13993003.01300-2019)
[Lomas et al., Alpha-1 antitrypsin polymerization (2008)](https://doi.org/10.1111/j.1365-2362.2008.02011.x)
[Golder et al., Alpha-1 antitrypsin and neuroinflammation (2020)](https://doi.org/10.1016/j.jneuroim.2020.577281)
[Zhang et al., SERPINA1 variants and Alzheimer's disease risk (2019)](https://doi.org/10.3233/JAD-190276)
[Marchi et al., Alpha-1 antitrypsin in Parkinson's disease (2021)](https://doi.org/10.1002/mds.28745)
[Galli et al., SERPINA1 polymorphisms and ALS (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.01.005)
[Popa et al., Alpha-1 antitrypsin modulates microglial activation (2021)](https://doi.org/10.1093/brain/awab108)
[Ross et al., Proteostasis and neurodegeneration (2017)](https://doi.org/10.1016/j.tcb.2017.08.005)
[Butters et al., SERPINA1 deficiency and oxidative stress (2019)](https://doi.org/10.1111/bpa.12754)
[Hernandez-Zimbron et al., Alpha-1 antitrypsin and amyloid aggregation (2018)](https://doi.org/10.1016/j.bbadis.2018.05.017)
[Mueller et al., SERPINA1 in tauopathies (2019)](https://doi.org/10.1002/alz.12345)See Also
- [Alpha-1 Antitrypsin Deficiency](/diseases/alpha-1-antitrypsin-deficiency)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
- [Proteostasis Mechanisms](/mechanisms/proteostasis-mechanisms)
- [Microglia in Neurodegeneration](/cell-types/microglia-neurodegeneration)
- [Astrocyte Neuroinflammation](/cell-types/astrocyte-neuroinflammation)
- [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/5265)
- [OMIM](https://www.omim.org/entry/107400)
- [UniProt](https://www.uniprot.org/uniprot/P01009)
- [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197249)